InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
RDaily Free
07/10/21 10:38 AM
profile icon
ssc Free
07/10/21 9:52 AM
profile icon
Ahjon81 Terminated
07/10/21 8:57 AM
profile icon
ssc Free
07/09/21 11:34 AM
profile icon
ssc Free
07/08/21 4:53 PM
profile icon
ssc Free
07/08/21 2:50 PM
profile icon
mr positivity Free
07/08/21 11:40 AM
profile icon
ssc Free
07/08/21 9:26 AM
profile icon
goforthebet Free
07/08/21 4:56 AM
profile icon
MSDR Free
07/07/21 12:00 PM
profile icon
MSDR Free
07/07/21 10:58 AM
profile icon
RDaily Free
07/07/21 10:52 AM
profile icon
ssc Free
07/07/21 10:34 AM
profile icon
Ahjon81 Terminated
07/06/21 7:43 PM
profile icon
Herold Free
07/06/21 11:05 AM
profile icon
Herold Free
07/06/21 11:04 AM
profile icon
ssc Free
07/06/21 11:01 AM
profile icon
Herold Free
07/06/21 10:57 AM
profile icon
ssc Free
07/06/21 10:43 AM
profile icon
Ahjon81 Terminated
07/06/21 10:31 AM
profile icon
MSDR Free
07/06/21 10:23 AM
profile icon
Herold Free
07/06/21 10:16 AM
profile icon
Herold Free
07/06/21 10:11 AM
profile icon
ssc Free
07/06/21 9:53 AM
profile icon
Ahjon81 Terminated
07/06/21 9:41 AM
profile icon
MSDR Free
07/06/21 9:39 AM
profile icon
SF Wolf Free
07/06/21 8:17 AM
profile icon
Ahjon81 Terminated
07/06/21 7:38 AM
profile icon
Herold Free
07/02/21 4:26 PM
profile icon
locicat1 Free
07/02/21 2:20 PM
profile icon
Herold Free
07/02/21 1:54 PM
profile icon
Herold Free
07/02/21 1:50 PM
profile icon
ssc Free
07/02/21 1:35 PM
profile icon
locicat1 Free
07/02/21 1:21 PM
profile icon
Herold Free
07/02/21 10:19 AM
profile icon
ssc Free
07/02/21 9:13 AM
profile icon
Threeflight Free
07/01/21 8:37 PM
profile icon
Herold Free
07/01/21 6:01 PM
profile icon
ssc Free
07/01/21 5:56 PM
profile icon
Herold Free
07/01/21 4:28 PM
profile icon
ssc Free
07/01/21 10:21 AM
profile icon
Ahjon81 Terminated
07/01/21 10:11 AM
profile icon
RDaily Free
06/28/21 7:06 PM
profile icon
Herold Free
06/28/21 5:59 PM
profile icon
ssc Free
06/28/21 3:03 PM
profile icon
goforthebet Free
06/28/21 1:40 PM
profile icon
ssc Free
06/28/21 12:34 PM
profile icon
Ahjon81 Terminated
06/24/21 10:02 AM
profile icon
goforthebet Free
06/24/21 4:41 AM
profile icon
Herold Free
06/23/21 2:49 PM

Biostax Corp (BTAX) RSS Feed

Followers
137
Posters
548
Posts (Today)
0
Posts (Total)
18220
Created
03/09/06
Type
Free
Moderators

 

IMUN - Immune Therapeutics

Contact Info

 

  • 37 North Orange Ave
    Suite 607
    Orlando, FL 32801



     
  •  
    •  
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
      Share Structure

       
    Shareholders of Record 808     a/o Apr 16, 2019
    Short Selling Data
    Equity Short Interest 4000
    as of March 13, 2020
    Significant Failures to Deliver No



     
           
      Authorized Shares 750,000,000 a/o May 4, 2020
      Outstanding Shares 457,577,799 a/o May 4, 2020






Quick Links:
www.immunetherapeutics.com
www.cytocom.com (subsidiary of IMUN - Cytocom will get eventual U.S. sales - if that ever happens - hopefully in 2-3 years?? IMUN owns 16.95% of Cytocom as of June 30, 2018. LDN has already received various Phase 2 approvals in the United States, see www.cytocom.com/investors/)
www.fidson.com (partner in Nigeria for marketing and distribution)

http://www.acromaxdominicana.com/ (partner for manufacturing in Dominican Republic - contract in 8-k)
http://www.omaera.com/ (partner in Kenya for marketing and distribution)
www.aharpharma.com (partner in Nigeria)



Important Links:

HIV Eradication 7 minute video, Oyagen

Kevin Phelps, CFO of Oyagen

Kevin Phelps (already on board of IMUN) becomes Interim CEO of IMUN, Michael Handley focusing on role as CEO of Cytocom and Forte Biotechechnology

https://m.youtube.com/watch?v=iydWaAmHblM

Youtube Video on Covid19 and low dose naltrexone

IMUN and Cytocom will collaborate to develop therapies for COVID19

IMUN provides guidance on reverse stock split and name change (reverse stock split first announced in 2018)

ImQuest Biosciences

Patent

IMUN appoints Michael Sander to board

Michael Handley is new CEO and president of IMUN

IMUN adds Kevin Phelps to the Board of Directors

Research on Lodonal in A & U Magazine

10-q from Q3 2018: IMUN ships first 250k pills to Fidson Healthcare (pg 25)

Ambassador Jack Brewer joins IMUN's board of directors

IMUN labeled as Pioneer in article in Forbes magazine

Dr Gary Blick, renown HIV specialist, joins IMUN's scientific advisory board

IMUN adds former US Assistant Surgeon General, Dr Roscoe Moore, as the new Chairman of the Board

Video from AIDS 2018 conference - starts at 59:58

IMUN acquires 10% stake in Cytocom

Research on Lodonal for HIV featured in Plus Magazine

Link to HIV Plus Magazine article on Lodonal

IMUN announces publication of White Paper on Lodonal 

8-k from 5/22/18: Fidson Healthcare accepts its appointment as the sole distributor of Lodonal in Nigeria

CNN Video interviewing Fidelis Ayebae, CEO of Fidson Healthcare

Form SC 13G from 5/15/18: Iliad Research and Trading owns 9.99% stake in Immune Therapeutics

8-k from 4/27/18: Kenya Pharmacy and Poison board files NDA for Lodonal for final review

IMUN received minutes from FDA Meeting for Lodonal for Crohn's Disease

First order shipped. First revenues for IMUN for $195k from AHAR Pharma


System for Award Management (companies need to register here to qualify for UNAIDS and other goverment grants) - Click on search records, then type in Immune Therapeutics.

8-k from 12/1/17: Shareholder letter - AHAR issues IMUN its first ever purchase order of $195,000 

10-Q from 11/14/17: IMUN lists $214k in inventory. First time ever listing having inventory on a 10-q or 10-k in IMUN's history

8-k from 11/2/17 - Note with Iliad Research and Trading

8-k from 9/8/17: IMUN announces exclusive agreement with Omaera Pharmaceuticals for Lodonal in Kenya - valued at a minimum of $31m in revenue over 3 years - first purchase order contractually guaranteed by 11/22/17

Kenya Agriculture, Fish, and Food Authorities: Approved List of Suppliers, Human Drugs and Medicine - Omaera Pharmaceuticals is on the list

8-k from 8/25/17: IMUN hires new COO Rudy Williams and hires new CEO of Cytocom Dr. John H Abeles (Dr. John H Abeles will also be new senior executive advisor of IMUN)

10-Q from 8/14/17: IMUN records first GAIN ever in shareholder equity for a quarter, and achieves this on NO REVENUE (due to elimination of toxic debt)

8-k from 4/27/16: LDN is approved in Nigeria

 

"The NAFDAC approval follows the successful completion of a 90-day bridging study conducted by AHAR Pharma on behalf of the Company in conjunction with State Specialist Hospital in Asubiaro. That study, “ A Bridging Study to Evaluate the Effects of ‘Lodonal’ as an Immune-System regulating Agent in Subjects in which Their Immune System is Compromised: Lodonal in the Treatment of Subjects with Human Immuno-Deficiency virus (HIV), ” met the primary and secondary endpoints for both efficacy and safety.

Breakthrough Lodonal Results on HIV Patients:

 The 90-Day Bridging Study was undertaken at the State Specialist Hospital in Asubiaro, Osogbo, Osun State, Nigeria and the primary objective of this Bridging trial was to confirm that Lodonal had a beneficial effect on the immune system of immune deficient patients and safety. This was a single center, open labeled, randomized, bridging study of a 150 people. The Treatment Group was treated with 4.5 mg of Lodonal nightly in conjunction with antiretroviral. The Control Group was treated with antiretroviral plus placebo The primary endpoints were efficacy and safety determined by a minimum increase of 25% in the CD4 count with no adverse effects on quality of life.

The results yielded an average 44% increase in CD4 count in the Treatment Group compared with 11% increase for the Control Group and there was no adverse effect on quality of life or opportunistic infections during the trial. The Nigeria trial’s results were consistent with previous clinical trials of LDN.

Due to its favorable cost/benefit, the Company believes Lodonal has large market potential to be the first affordable non-toxic therapy of its kind. It is administered in a single oral dose daily making medical and drug compliance much easier and is designed to produce a significant reduction in opportunistic infections. In addition to affordably improving the quality of patients’ lives, it offers a compelling economic benefit to health care systems.